Literature DB >> 35060132

Human papillomavirus genotype concordance between Anyplex II HPV28 and linear array HPV genotyping test in anogenital samples.

François Coutlée1,2,3,4, Alexandra de Pokomandy5,6, Ann N Burchell7,8, Mariam El-Zein4, Marie-Hélène Mayrand2,3, Sophie Rodrigues-Coutlée1, Deborah Money9, Émilie Comète1, Elisabeth McClymont9, Danielle Rouleau2,3, Eduardo L Franco4.   

Abstract

Anyplex II HPV-28 (HPV-28) can detect individually 28 HPV genotypes. We assessed the agreement between linear array HPV genotyping (LA-HPV) and HPV-28 for detection of 27 HPV genotypes in 410 stored anogenital samples (75 anal samples, 335 physician-collected cervical samples) collected over 5 years from 410 individuals (13 men, 397 women), including 202 HIV-seropositive individuals. HPV DNA was detected in 393 (95.9%, 95% confidence interval [CI]: 93.4-97.4) and 382 (93.2%, 95% CI: 90.3-95.3) samples with HPV-28 and LA-HPV (p = 0.13), respectively, for a good agreement of 96.3% (κ = 0.65). Of the 10503 HPV typing results, 10195 (780 positive, 9577 negative) were concordant, for an agreement of 97.1% (95% CI: 96.7-97.4) and an excellent of κ = 0.82 (95% CI: 0.80-0.84). The mean type-specific concordance for 27 genotypes was 97.0%, 95% CI: 95.8-98.5 (κ = 0.86 ± 0.07, 95% CI: 0.83-0.88). Excellent agreement was obtained individually for all high-risk genotypes (κ = 0.81-0.97) and for most other genotypes except for types 42, 44, 54, 68, and 69. The mean number of types per sample in discordant samples detected with LA-HPV (3.0, 95% CI: 2.7-3.4) was greater than in concordant samples (1.4, 95% CI: 1.3-1.5; p< 0.001). In conclusion, HPV-28 compared favorably with LA-HPV, but was more frequently positive for HPV42 and HPV68.
© 2022 Wiley Periodicals LLC.

Entities:  

Keywords:  HPV; PCR; consensus PCR; genital cancer; genotyping

Mesh:

Substances:

Year:  2022        PMID: 35060132      PMCID: PMC9126003          DOI: 10.1002/jmv.27605

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   20.693


  33 in total

1.  The 2010 global proficiency study of human papillomavirus genotyping in vaccinology.

Authors:  Carina Eklund; Ola Forslund; Keng-Ling Wallin; Tiequn Zhou; Joakim Dillner
Journal:  J Clin Microbiol       Date:  2012-04-25       Impact factor: 5.948

2.  A review of human carcinogens--Part B: biological agents.

Authors:  Véronique Bouvard; Robert Baan; Kurt Straif; Yann Grosse; Béatrice Secretan; Fatiha El Ghissassi; Lamia Benbrahim-Tallaa; Neela Guha; Crystal Freeman; Laurent Galichet; Vincent Cogliano
Journal:  Lancet Oncol       Date:  2009-04       Impact factor: 41.316

3.  Comparison of the analytical and clinical performance of five tests for the detection of human papillomavirus genital infection.

Authors:  M Del Pino; I Alonso; A Rodriguez-Trujillo; S Bernal; D Geraets; N Guimerà; A Torne; J Ordi
Journal:  J Virol Methods       Date:  2017-07-21       Impact factor: 2.014

4.  Global proficiency study of human papillomavirus genotyping.

Authors:  Carina Eklund; Tiequn Zhou; Joakim Dillner
Journal:  J Clin Microbiol       Date:  2010-09-15       Impact factor: 5.948

5.  Confirmatory real-time PCR assay for human papillomavirus (HPV) type 52 infection in anogenital specimens screened for HPV infection with the linear array HPV genotyping test.

Authors:  François Coutlée; Danielle Rouleau; Georges Ghattas; Catherine Hankins; Sylvie Vézina; Pierre Coté; John Macleod; Alexandra de Pokomandy; Deborah Money; Sharon Walmsley; Hélène Voyer; Paul Brassard; Eduardo Franco
Journal:  J Clin Microbiol       Date:  2007-09-26       Impact factor: 5.948

6.  Clinical validation of Anyplex™ II HPV HR Detection according to the guidelines for HPV test requirements for cervical cancer screening.

Authors:  A T Hesselink; R Sahli; J Berkhof; P J F Snijders; M L van der Salm; D Agard; M C G Bleeker; D A M Heideman
Journal:  J Clin Virol       Date:  2016-01-15       Impact factor: 3.168

7.  Global improvement in genotyping of human papillomavirus DNA: the 2011 HPV LabNet International Proficiency Study.

Authors:  Carina Eklund; Ola Forslund; Keng-Ling Wallin; Joakim Dillner
Journal:  J Clin Microbiol       Date:  2013-11-20       Impact factor: 5.948

8.  Maternal human papillomavirus infections at mid-pregnancy and delivery in a Scandinavian mother-child cohort study.

Authors:  Magdalena R Værnesbranden; Johanna Wiik; Katrine Sjøborg; Anne Cathrine Staff; Karin C Lødrup Carlsen; Guttorm Haugen; Gunilla Hedlin; Katarina Hilde; Björn Nordlund; Camilla F Nystrand; Anbjørg Rangberg; Eva Maria Rehbinder; Knut Rudi; Corina Silvia Rueegg; Yvonne Sandberg; Sigrid Sjelmo; Håvard O Skjerven; Cilla Söderhäll; Riyas Vettukattil; Christine M Jonassen
Journal:  Int J Infect Dis       Date:  2021-05-30       Impact factor: 3.623

Review 9.  Commercially available molecular tests for human papillomaviruses (HPV): 2015 update.

Authors:  Mario Poljak; Boštjan J Kocjan; Anja Oštrbenk; Katja Seme
Journal:  J Clin Virol       Date:  2015-11-05       Impact factor: 3.168

10.  Clinical and Analytical Evaluation of the Anyplex II HPV HR Detection Assay within the VALGENT-3 Framework.

Authors:  Anja Oštrbenk; Lan Xu; Marc Arbyn; Mario Poljak
Journal:  J Clin Microbiol       Date:  2018-10-25       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.